Clinical Trials

42 enrolled

HR Positive/HER-2 Negative Breast Cancer

NCT05574881 2024-02-26

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

72 enrolled

Breast Neoplasms

NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

120 enrolled

Breast Neoplasms

NCT06047184 2023-09-21

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

106 enrolled

Advanced Breast Cancer

NCT05433480 2023-07-27

A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

274 enrolled

Breast Neoplasms

NCT05806047 2023-04-10

Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy

23 enrolled

Hormone Receptor-positive Advanced Breast Cancer

NCT05806671 2023-04-10

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

30 enrolled

Breast Neoplasms

NCT05792410 2023-03-31

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

300 enrolled

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

59 enrolled

Breast Neoplasms

NCT02983071 2023-02-15

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

102 enrolled

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

73 enrolled

Breast Neoplasms

NCT05577923 2022-10-13

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

126 enrolled

Breast Neoplasms

NCT05186545 2022-09-02

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

63 enrolled

Breast Neoplasms

NCT05504213 2022-08-17

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

224 enrolled

Breast Neoplasms

NCT04334330 2022-05-02

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

34 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT05000736 2022-04-29

CAPACITY

600 enrolled

Hormone Receptor Positive Advanced Breast Cancer

NCT02909361 2022-04-20

Fulvestrant 500mg in Patients With Advanced Breast Cancer

500 enrolled

Breast Neoplasms

NCT02626507 2022-02-09

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

18 enrolled

Breast Neoplasms

NCT05140655 2021-12-01

Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-

40 enrolled

Breast Neoplasm Female

NCT03633331 2021-10-15

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

93 enrolled 8 charts

Estrogen Receptor-positive Breast Cancer

NCT05076695 2021-10-13

NeoTPPF

37 enrolled

Estrogen Receptor-positive Breast Cancer

NCT05047848 2021-09-17

Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer

Phase NA Unknown

82 enrolled

Advanced Breast Cancer

NCT04999540 2021-08-11

Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer

73 enrolled

Breast Neoplasms

NCT04936295 2021-06-23

Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

61 enrolled

Breast Neoplasms

NCT03927456 2021-06-03

A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

357 enrolled

Advanced Breast Cancer

NCT04856371 2021-04-23

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

228 enrolled

Advanced Breast Cancer

NCT04852081 2021-04-21

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

1,000 enrolled

Breast Neoplasms

NCT04753177 2021-02-15

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Phase 2/3 Unknown

120 enrolled

The Neoadjuvant Therapy

NCT04034589 2020-12-22

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

46 enrolled

Breast Neoplasms

NCT04355520 2020-04-21

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

42 enrolled

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

NCT04289974 2020-02-28

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

100 enrolled

Breast Neoplasms

NCT02690480 2020-02-05

FLIPPER

189 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03024580 2019-08-15

MEGA

20 enrolled

Breast Neoplasms

NCT04033172 2019-07-25

Pyrotinib

40 enrolled

Breast Neoplasms

NCT03925233 2019-04-24

Breast Cancer Treatment Based on Organ-like Culture

300 enrolled

Breast Cancer Organoids

NCT00006903 2019-03-20

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

67 enrolled 9 charts

Gynecologic

Recurrent Uterine Corpus Carcinoma

NCT03182634 2019-01-22

plasmaMATCH

1,150 enrolled

Advanced Breast Cancer

NCT03591549 2018-07-23

Fulvestrant in Metastatic Breast Cancer

Phase 4 Unknown

30 enrolled

Breast Neoplasms

NCT02000193 2018-07-10

FANCY

58 enrolled

Breast Neoplasms

NCT03560856 2018-06-18

PALPETBIO

54 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03202862 2017-06-29

The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer

50 enrolled

Breast Neoplasms

NCT01266213 2017-05-01

FLAG

147 enrolled

Breast Neoplasms

NCT02646735 2017-01-02

FRIEND

148 enrolled

Breast Neoplasms

NCT02383030 2016-06-15

FUMANCE

156 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02394496 2016-06-15

OVER

396 enrolled

Breast Neoplasms

NCT02404051 2016-06-15

FEVEX

745 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02530411 2015-08-21

FURVA

160 enrolled

Tumor-Agnostic

Neoplasms

NCT02072512 2014-02-26

PROOF

180 enrolled

Breast Neoplasms

NCT00126464 2013-11-06

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

Phase NA Unknown

100 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT00688194 2013-08-26

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

396 enrolled